India to introduce more advanced testing for imported blood products to reduce infection risk
New Delhi: The health ministry plans to mandate the use of a faster and more accurate method to test all imported blood products to maintain the highest safety standards and reduce the risk of infection from transfusions.
The ministry intends to introduce nucleic acid testing (NAT) to improve the screening of imported blood products for antibodies of the human immunodeficiency virus (HIV), the hepatitis B virus, the hepatitis C virus and other impurities, an official aware of the matter said.
The decision to shift to NAT has already been taken by the regulator, the Drug Controller General of India (DCGI), and the matter was discussed at the Drugs Technical Advisory Board meeting in April. The board is the highest statutory body responsible for advising the Central and state governments on technical matters related to the administration of the Drugs and Cosmetics Act, 1940.
Also Read | Banking on blood: Health ministry frames guidelines to curb paid donations, improve efficacy of transfusions
With the introduction of NAT, the conventional testing method known as ELISA, or enzyme-linked immunosorbent assay, will be done away with. ELISA, while a powerful tool, has several drawbacks, including the potential for false positive and negative results, apart from being time-consuming.
The Department of Pharmaceuticals and the National Institute of Biologicals (NIB) in Noida had issued an alert in October after the NIB found three imported blood products—Berirab-P (used in rabies injections), Hepabig (to prevent hepatitis B virus infection) and Tetglob (used for tetanus treatment)—to be of sub-standard quality.
When the Berirab-P and Hepabig samples were tested again at the National Institute of Virology in Pune using an advanced version of polymerase chain reaction, which is more sensitive than ELISA, they passed the test metrics. The set of Tetglob samples sent to a private laboratory that used ELISA were non-reactive.
Safety standards
Bharat Serums and Vaccines Ltd, now owned by Mankind Pharma, is the only company in the country that imports these lifesaving blood products.
Imported blood products are used for the treatment of critically ill patients or those who are suffering thalassemia and other blood-related disorders. These products are tested at government laboratories to ensure they meet safety and quality standards.
Also Read | India plans standard evaluation and quality protocols for HMPV' testing kits
'These are tested using conventional methods, but now the plan is to amend the rules to allow an advanced version of testing in line with international practices," the official said. 'NIB also proposed that an amendment may be considered to test blood products by NAT."
Queries sent to the health ministry, the Department of Pharmaceuticals and the Mankind Pharma spokesperson remained unanswered till press time.
'NAT testing gives accurate and quick results and nowadays it is highly used. NAT testing is used for tuberculosis and NAT testing was modified during the covid-19 pandemic to detect the coronavirus," a scientist from the Indian Council of Medical Research said, requesting anonymity. 'The ELISA test may sometimes give false results if the viral load in the sample is low. However, PCR and NAT give accurate results even if the viral load is low."
Also Read | ICMR and CDSCO develop framework for validation of pathogen identification and antimicrobial susceptibility testing
According to an assessment by the National Blood Transfusion Council, the apex policymaking body for issues pertaining to blood and plasma, the clinical requirement of blood in the country is about 14.5 million units per year. The volume of each unit of blood is about 450 ml.
In India, the import, manufacture, distribution and sale of drugs, cosmetics and notified medical devices are regulated by the Drugs and Cosmetics Act and the Drugs and Cosmetics Rules, 1945.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Time of India
4 days ago
- Time of India
State govt puts cap of Rs 600 again for dengue test
1 2 3 Pune: The state govt has again capped the price of ELISA test for dengue at Rs 600 while issuing fresh directives to all hospitals and laboratories amid a rise in vector-borne infections like dengue and chikungunya this monsoon. The rate has remained unchanged since 2016. In 2015, Delhi became the first state to cap the rate of dengue test at Rs 600, which was then followed by Maharashtra. Pune Municipal Corporation officials have urged patients to lodge a complaint in case any hospital or laboratory is found to be charging more than the capped amount. The state health department has been telling diagnostic labs and hospitals since 2016 to cap the cost during monsoon to make these tests affordable for patients. However, it is often seen that labs overcharge anywhere between Rs800 and Rs1,100 per test, which deters patients from undergoing a proper evaluation. Dr Sandeep Sangale, joint director, health services, Maharashtra, said, "Since 2016, the state has ordered all private hospitals and labs to conduct NS1 ELISA and MAC ELISA dengue tests within Rs 600 to ensure that there is no exploitation of patients by these labs or hospitals. We have also instructed the labs to make sure that under no circumstances do they use rapid diagnostic kits to test dengue samples and stick to ELISA tests only for confirming dengue. We have sent the circular to all directors under the health department and the concerned medical officers in civic bodies and zilla parishads as well." Confirming the same, Dr Nina Borade, chief health officer, PMC health department, said, "We have received the circular and issued a notification to all the private labs and hospitals registered with us to ensure that they do not charge more than Rs 600 for a dengue ELISA test. We also urge citizens to come forward if they find any lab or hospital charging more than the stipulated amount. During monsoon we see a surge in the number of cases and so the govt has capped the prices to make sure that everyone can afford these tests, which are important for determining the course of treatment. " Borade said that citizens can mail their complaints to health@ or contact the department on 020- 25501215 Meanwhile, Indian Medical Association (IMA) has stated that while most members do comply with the govt guidelines, there is disagreement among some regarding the capping. Dr Sanjay Patil, chairperson, Hospital Board of India, IMA Pune chapter, said, "The feasibility of any cost for any diagnostic test or procedure depends on the material used and the infrastructure involved. Every hospital or a diagnostic center has the freedom to decide the rate for the investigation but considering that dengue is prevalent in Pune and for the time being the govt has put these restrictions, so all private hospitals are following the govt guidelines. However there is some unrest among the hospitals on price capping which has remained the same since 2016." On Wednesday, TOI reported that an early monsoon had triggered a surge in vector-borne infections in the state as the number of cases has surpassed those reported in 2024 for the first six months. Pune also has seen a surge in the number of vector-borne infections. Altogether 169 suspected and eight confirmed dengue cases have been reported this year of which 62 suspected and two confirmed were reported in May and June (till 18). Also, eight chikungunya cases have been reported in Pune city this year. Pune: The state govt has again capped the price of ELISA test for dengue at Rs 600 while issuing fresh directives to all hospitals and laboratories amid a rise in vector-borne infections like dengue and chikungunya this monsoon. The rate has remained unchanged since 2016. In 2015, Delhi became the first state to cap the rate of dengue test at Rs 600, which was then followed by Maharashtra. Pune Municipal Corporation officials have urged patients to lodge a complaint in case any hospital or laboratory is found to be charging more than the capped amount. The state health department has been telling diagnostic labs and hospitals since 2016 to cap the cost during monsoon to make these tests affordable for patients. However, it is often seen that labs overcharge anywhere between Rs800 and Rs1,100 per test, which deters patients from undergoing a proper evaluation. Dr Sandeep Sangale, joint director, health services, Maharashtra, said, "Since 2016, the state has ordered all private hospitals and labs to conduct NS1 ELISA and MAC ELISA dengue tests within Rs 600 to ensure that there is no exploitation of patients by these labs or hospitals. We have also instructed the labs to make sure that under no circumstances do they use rapid diagnostic kits to test dengue samples and stick to ELISA tests only for confirming dengue. We have sent the circular to all directors under the health department and the concerned medical officers in civic bodies and zilla parishads as well." Confirming the same, Dr Nina Borade, chief health officer, PMC health department, said, "We have received the circular and issued a notification to all the private labs and hospitals registered with us to ensure that they do not charge more than Rs 600 for a dengue ELISA test. We also urge citizens to come forward if they find any lab or hospital charging more than the stipulated amount. During monsoon we see a surge in the number of cases and so the govt has capped the prices to make sure that everyone can afford these tests, which are important for determining the course of treatment. " Borade said that citizens can mail their complaints to health@ or contact the department on 020- 25501215 Meanwhile, Indian Medical Association (IMA) has stated that while most members do comply with the govt guidelines, there is disagreement among some regarding the capping. Dr Sanjay Patil, chairperson, Hospital Board of India, IMA Pune chapter, said, "The feasibility of any cost for any diagnostic test or procedure depends on the material used and the infrastructure involved. Every hospital or a diagnostic center has the freedom to decide the rate for the investigation but considering that dengue is prevalent in Pune and for the time being the govt has put these restrictions, so all private hospitals are following the govt guidelines. However there is some unrest among the hospitals on price capping which has remained the same since 2016." On Wednesday, TOI reported that an early monsoon had triggered a surge in vector-borne infections in the state as the number of cases has surpassed those reported in 2024 for the first six months. Pune also has seen a surge in the number of vector-borne infections. Altogether 169 suspected and eight confirmed dengue cases have been reported this year of which 62 suspected and two confirmed were reported in May and June (till 18). Also, eight chikungunya cases have been reported in Pune city this year.
The Hindu
4 days ago
- The Hindu
Primary Health Centres can be approached for hepatitis B vaccine, says TN govt
With a number of private hospitals continuing to face a shortage of Hepatitis B vaccines, the Directorate of Public Health and Preventive Medicine has said that the nearest Primary Health Centre (PHC) can be approached for vaccinating children against hepatitis B as per Universal Immunisation Programme (UIP) schedule. Several private hospitals across the State have been facing short supply of hepatitis B vaccines especially for vaccinating their healthcare workers and patients such as those on dialysis. A private hospital in Chennai that administers both pentavalent and hexavalent vaccines containing hepatitis B under UIP currently has adequate stock. The Health department said that there was no shortage of the vaccine in government hospitals. Health Minister Ma. Subramanian recently said that the State had a stock of 6,21,320 doses of the vaccine at present. This was adequate to meet the requirements for 8.5 months. Similarly, 5,52,100 pentavalent vaccines were also available to take care of the needs for the next 2.5 months. T. S. Selvavinayagam, Director of Public Health, reiterated that nearby PHCs can be approached for vaccinating children as per UIP schedule. A doctor, who has been closely following the hepatitis B vaccine situation, said that Hepatitis B vaccination in adults is always challenging. It was being implemented by covering key populations who have been screened and found as hepatitis negative before vaccination, he said. Open Vial Policy for hepatitis B vaccine to prevent wastage is one of the main challenges. This allows usage of an open vial for up to 28 days. 'The vaccine is administered to the targeted groups (among adults) after hepatitis B testing. In fact, the test kits are also in short supply' he said.
The Hindu
5 days ago
- The Hindu
Karnataka to roll out Hepatitis B vaccination drive for healthcare workers
With stocks of over two lakh doses of the Hepatitis B vaccine, the Karnataka Health Department is all set to roll out a drive to vaccinate all healthcare workers against the viral infection that causes inflammation in the liver. The drive, being taken up under the National Viral Hepatitis Control Programme (NVHCP), will cover over 56,000 healthcare workers who have reasonably anticipated risks for exposure to infectious materials, including blood or bodily fluids, contaminated medical supplies and equipment, or contaminated environmental surfaces, said a senior official in charge of the programme. According to a circular issued by the State Deputy Director (NVHCP) in this regard on Wednesday, June 18, each healthcare worker will be administered three doses of the intramuscular injection into the upper arm at a gap of one month and six months respectively after the first dose. Hepatitis B vaccine stocks have been supplied by the central division to the state vaccine warehouse in Bengaluru. The stocks are now being dispatched to the district drug warehouses as per the requirement. The vaccine should be administered to all health workers (medical and paramedical staff) working in the sub-centre, primary, and community health centres, and taluk and district hospitals of the respective district, the circular stated. The vaccine supplied to the district drug warehouses should be in coordination with the Reproductive and Child Health (RCH) officers to understand the requirement under the routine immunisation programme. The District Tuberculosis Control Officers should take action in supplying the vaccine and administering it to the eligible beneficiaries. The report of vaccination to the beneficiaries should be entered in the NVHCP/MIS portal, and the staff will soon be trained on administering the vaccine and reporting, the circular added.
